Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients

American Journal of Hematology
Mahnur HaiderAyalew Tefferi

Abstract

The primary objective of treatment in essential thrombocythemia (ET) is to prevent thromboembolic complications. In this regard, advanced age and thrombosis history have long distinguished "low" from "high" risk patients. More recently, JAK2V617F and cardiovascular (CV) risk factors were identified as additional modifiers, leading to the development of a 3-tiered International Prognostic Score of Thrombosis for ET (IPSET-thrombosis): "low," "intermediate," and "high". The international data set used to develop IPSET-thrombosis was recently re-analyzed in order to quantify the additional pro-thrombotic effect of JAK2V617F and CV risk factors in specific risk subcategories. The revised IPSET-thrombosis identified four risk categories based on three adverse variables (thrombosis history, age >60 years and JAK2V617F): very low (no adverse features), low (presence of JAK2V617F), intermediate (age >60 years) and high (presence of thrombosis history or presence of both advanced age and JAK2V617F). In this study of 585 patients with ET (median age 68 years; 61% female), we validated the revised IPSET-thrombosis by confirming significant differences in thrombosis risk between "very low" and "low" (HR 2.4, 95% CI 1.1 - 5.3) and between "...Continue Reading

References

Jan 23, 2015·American Journal of Hematology·Ayalew Tefferi, Tiziano Barbui
Mar 21, 2015·Clinical Lymphoma, Myeloma & Leukemia·Omur Gokmen SevindikGuner Hayri Ozsan
Apr 16, 2015·American Journal of Hematology·Ayalew Tefferi, Tiziano Barbui
Jul 17, 2015·JAMA Oncology·Ayalew Tefferi, Animesh Pardanani
Sep 12, 2015·Mayo Clinic Proceedings·Ayalew Tefferi, Tiziano Barbui

❮ Previous
Next ❯

Citations

Feb 4, 2016·American Journal of Hematology·Tiziano Barbui
Apr 14, 2016·Thrombosis Research·Tiziano Barbui, Anna Falanga
Jun 6, 2006·Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology·Alice Y KuoD Michael Denbow
Dec 12, 2017·Obstetric Medicine·Mathieu PuyadeOlivier Pourrat
Aug 29, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anna L GodfreyUNKNOWN and the Australasian Leukaemia and Lymphoma Group.
Feb 23, 2019·Expert Review of Hematology·Barbara Mora, Francesco Passamonti
Dec 7, 2018·Hematology·Michele Ciboddo, Ann Mullally
May 24, 2019·European Journal of Haematology·Vincenzo AccursoSergio Siragusa
May 31, 2020·Molecular Biology Reports·Mohsen MalekniaNajmaldin Saki
Jul 21, 2020·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Xueya ZhangJingxin Pan
Feb 26, 2020·Leukemia & Lymphoma·Ivan KrečakNadira Duraković
May 21, 2019·Frontiers in Oncology·Giuseppe A PalumboAlessandra Iurlo
Nov 28, 2019·The New England Journal of Medicine·Ayalew Tefferi, Animesh Pardanani
May 14, 2020·Current Hematologic Malignancy Reports·Carlos Galvez, Brady L Stein
Jan 13, 2018·Blood Cancer Journal·Ayalew TefferiTiziano Barbui
Feb 27, 2020·Blood Cancer Journal·Paola GuglielmelliTiziano Barbui
Jun 10, 2020·International Journal of Hematology·Ivan KrečakVelka Gverić-Krečak
Apr 14, 2020·Advances in Hematology·Salvatrice MancusoSergio Siragusa
Sep 26, 2020·American Journal of Hematology·Ayalew Tefferi, Tiziano Barbui
Dec 10, 2020·American Journal of Hematology·Naseema Gangat, Ayalew Tefferi
Jan 22, 2021·The Journal of International Medical Research·Xuhui ChenXuming Huang
Jan 16, 2021·Clinical Medicine Insights. Blood Disorders·Vincenzo AccursoSergio Siragusa
Dec 10, 2020·OncoTargets and Therapy·Giuseppe G LoscoccoAlessandro M Vannucchi
Dec 27, 2017·Clinical Lymphoma, Myeloma & Leukemia·Prithviraj BoseSrdan Verstovsek
Apr 22, 2021·HemaSphere·Andrew J Robinson, Anna L Godfrey
Jun 5, 2021·Frontiers in Oncology·Juçara Gastaldi CominalFabíola Attié de Castro
Aug 18, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anish V ShardaJeffrey I Zwicker

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.